Target

NKGen Biotech Advances Alzheimer’s Treatment with SNK01: First Patient Dosed in Phase 1/2a Trial

December 29, 2023 - NKGen Biotech, Inc. (Nasdaq: NKGN) is making strides in Alzheimer's disease (AD) treatment with the dosing of the first patient in its Phase 1/2a trial for SNK01, an autologous natural killer (NK) cell therapy. The innovative product, designed for moderate AD, has demonstrated promising results in neuroinflammation and cognitive function during its Phase 1 safety trial. Key Points: SNK01 Efficacy: NKGen's SNK01, a cryopreserved autologous NK cell therapy, showed improvement in neuroinflammation and cognitive function in the Phase 1 dose-escalation safety trial. The therapy boasts enhanced

NEW APPEAL TO PROVIDE SUPPORT TO THOUSANDS OF ISRAELI CITIZENS FOLLOWING HAMAS ASSAULT

  Tel Aviv, New York & London; October 19, 2023: In the wake of the recent catastrophic and unprecedented attack that was launched at Israel by Hamas on and beyond October 7, Ahavat Yisroel Humanity Inc. has launched an urgent fundraising appeal in order to provide much-needed support and supplies to the thousands of Israeli citizens affected. The Israel Now, Israel Forever appeal is seeking donations to provide the many affected citizens with food, shelter, and urgent suppliers. The donations will be shared among four established and experienced relief organisations

The Tightrope of Regulation

In a significant move at the recent G20 meeting in India, the International Monetary Fund (IMF) and the Financial Stability Board (FSB) released a joint paper outlining a framework for the global regulation of cryptocurrencies. While the proposals mostly tread familiar territory, what’s new is their conviction in crypto’s unstoppable growth and success. A flurry of optimism greeted the G20’s endorsement of the report because it advocates that countries don’t ban crypto. Hidden in its text, however, are some worrying signs. For example, on the first page, they state, “Widespread

Coya Therapeutics Reports Additional Biomarker and Imaging Data Showing Decrease in Neuroinflammation with COYA 301 in Alzheimer’s Disease.

Highlights Coya reports new data illustrating that administration of COYA 301 (low dose Interleukin-2 (IL-2)) in an open- label study in 8 patients with mild to moderate AD (COYA 301 Trial) resulted in a statistically significant reduction in the expression of three well characterized proinflammatory cytokines -- Tumor Necrosis Factor alpha (TNF-α), Interleukin 6 (IL-6), and Interleukin 1- Beta (IL-1β) -- which correlated with lack of cognitive decline of the patients over the course of the study. TNF-α is one of the main inflammatory cytokines involved in initiating and propagating

Verofax to raise US$750,000 on Beban Crowdfunding Platform

- Offering GCC retail investors interactive access to private equity investment opportunities BAHRAIN, Mar 5, 2023 - (ACN Newswire) - Verofax, the leader in brand marketing and AI-powered solutions for enterprise, was featured on Beban 2 (Episode 9, Mar 1, 2023), the hit entrepreneur & investment-themed reality TV program airing on Bahrain TV, Alrai TV and Dubai TV, as well as Shahid, the region's largest video-on-demand platform.   Wassim Merheby, CEO & Co-Founder, and Jamil Zablah, CMO & Co-Founder, Veromax, a product winning SaaS provider helping brands achieve growth by turning offline products interactive

Mainnet Update

One of the silver linings, indeed perhaps the only silver lining, from the bear market disasters of the past few months has been the opportunity it afforded the Paribus development team to deploy our MVP via testnet. Even this however wasn’t free from challenges, so in this article, we dive a little deeper into what the next few weeks and months hold for Paribus. Our primary focus is to be able to transition from the testnet to the mainnet, but at the same time, we’ve also been limited by some

Minting Milestones and Multi-pass Usage

Author: Half BAYCD During this Sunday’s Smoke Sesh we passed the 40% minted mark, just 3 weeks after launch on 8/8. We’re very grateful and appreciative of the community we’re creating and we wouldn’t be able to do this project without you. On Sunday we announced the ability to use more than one pass per asset — when we initially launched the project the requirement was 1 pass = 1 asset license, this has now changed. The new model of stacking passes both increases your ability to exploit your asset’s

Web3 and online entertainment – how will it change?

The technology industry is buzzing with many new innovations. Metaverse, augmented and virtual reality and Web3 are just a few things that will change our everyday life and of course our perception of digital and technology. Web3 is a new version of the current internet network, which has been in use for decades. It is a network of shared source file based on blockchain technology that will revolutionize everything. Through it, you can enjoy an increasingly virtual and safer internet, where the sharing of your data is not decided by

Fastbase is Revolutionizing Lead Generation introducing Leads Navigator

“Fastbase is squaring the circle with Leads Navigator, the ultimate lead generator solution providing a strong revenue model for Fastbase, making 2022 a catalyst for financial growth.” Rasmus Refer, CEO Fastbase. Fastbase (OTC:FBSE) has just launched Leads Navigator, a lead generation tool to raise pipe-line generation standards for millions of sales and marketing professionals worldwide. Fastbase is primarily known for its popular WebLeads add-on to Google Analytics which is today used by more than 1.3 million companies and top brands from around the world. Fastbase analyzes more than 10 billion